98%
921
2 minutes
20
Several studies have reported a strong association between plasma proteins and chronic obstructive pulmonary disease (COPD). However, the directionality and causality of the association and whether proteins effected COPD remain unclear. Therefore, we used Proteome-wide Mendelian randomization (MR) study and co-localization analyses to estimate the casual relationship between them. Summary-level data of 2923 plasma protein levels were extracted from a large-scale protein quantitative trait loci study including 54,219 individuals by the UK Biobank Pharma Proteomics Project. The outcome data for COPD and its subtypes were sourced from the FinnGen study. MR analysis was conducted to estimate the associations between protein and COPD and its subtypes risk. Additionally, phenome-wide MR analysis, and candidate drug prediction were employed to identify potential causal circulating proteins and novel drug targets. STROBE MR guidelines are followed for the study. We assessed the effect of 1929 plasma proteins on COPD. We found that Seven proteins, 4 proteins, and 3 proteins were associated with overall COPD, early-onset COPD, and later-onset COPD risk, respectively. MHC class I polypeptide-related sequence B_A (MICB_MICA) and tyrosine-protein kinase receptor tie-1 (TIE-1) would increase 8% and 27% COPD risk (MICB_MICA: odds ratios [OR], 1.08; 95% CI, 1.05-1.10; PFDR = 2.53 × 10-5; TIE-1: OR, 1.27; 95% CI, 1.13-1.43; PFDR = .012). There was negative association of Septin-8 and Butyrophilin subfamily 1 member A1 (BTN1A1) with overall COPD risk (Septin-8: OR, 0.68; 95% CI, 0.57-0.79; PFDR = 8.00 × 10-4 BTN1A1: OR, 0.82; 95% CI, 0.75-0.90; PFDR = .010). There was a protective effect of BTN1A1 on early COPD incidence (OR, 0.72; 95% CI, 0.63-0.83; PFDR = .002). However, there was no evidence indicating a shared causal variant between the other proteins and COPD and its subtypes in these regions (all posterior probability.H4 < .8). The study revealed the causal relationship between several plasma proteins and COPD and its subtypes, providing new theoretical support for understanding COPD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074030 | PMC |
http://dx.doi.org/10.1097/MD.0000000000042409 | DOI Listing |
Pulm Ther
September 2025
Department of Pulmonary Function Test, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Introduction: Preserved ratio impaired spirometry (PRISm) is an important phenotype of pulmonary function in clinical and public health practice. It is possible for some patients to have chronic obstructive pulmonary disease (COPD) at an early stage. At present there is little research on the association of PRISm with type 2 (T2) inflammation biomarkers.
View Article and Find Full Text PDFImmunol Invest
September 2025
Respiratory and Critical Care Medicine, The 940th Hospital of Joint Logistics Support Force of chinese PLA, Lanzhou, China.
Background: Pulmonary neuroendocrine cells (PNECs) are specialized airway epithelial cells with dual sensory and secretory functions. They release bioactive mediators --including neuropeptides such as calcitonin gene-related peptide (CGRP) and gastrin-releasing peptide (GRP), and neurotransmitters such as 5-hydroxytryptamine (5-HT) and γ-aminobutyric acid (GABA) --that regulate airway smooth-muscle tone, mucus production, and immune responses. In chronic obstructive pulmonary disease (COPD), these PNEC-derived mediators contribute to airway inflammation, remodeling, and smooth-muscle dysfunction.
View Article and Find Full Text PDFRespir Med
September 2025
Scottish Centre for Respiratory Research, School of Medicine, University of Dundee, Dundee, United Kingdom. Electronic address:
Background: Eosinophilic chronic obstructive pulmonary disease (eCOPD), characterized by type 2 inflammation, is an emerging target for biologic therapies.
Objective: To indirectly compare the efficacy of dupilumab and mepolizumab in eCOPD, defined as blood eosinophil counts ≥300 cells/μL, by synthesizing data from phase 3 randomized controlled trials: BOREAS and NOTUS for dupilumab, MATINEE for mepolizumab.
Methods: We performed an indirect comparison of trial primary and secondary outcomes including annual exacerbation rates (AER), quality of life (St.
J Chromatogr B Analyt Technol Biomed Life Sci
September 2025
Center of Scientific Research, Basic Medical Science College, Qiqihar Medical University, Qiqihar, Heilongjiang Province,161006, China; Key Laboratory of Homology of Medicine and Food Resources and Metabolic Disease Prevention and Treatment of Heilongjiang Province, Qiqihar, Heilongjiang Province,16
Wendan Decoction (WDD), a classic formula for the expectoration of phlegm, has been acknowledged for the management of chronic obstructive pulmonary disease (COPD). Nevertheless, the therapeutic components and mechanism of WDD in COPD remain elusive. Hence, an analytical strategy for extensive investigation of the constituents in WDD combining UFLC-ESI-Q/TOF-MS and subsequent network pharmacology was conducted, and the appropriate preparation of bio-samples was involved with mechanistic bioanalysis including multi-technique metabolomics and molecular biological means, that pivotal factors such as PTGS2, arachidonic acid (AA) metabolism, and PI3K-AKT signaling pathway were recommended as potential central elements for the anti-COPD effects.
View Article and Find Full Text PDFComput Methods Programs Biomed
September 2025
School of Biological Sciences and Medical Engineering, Southeast University, Nanjing, Jiangsu, China. Electronic address:
Background And Objective: The quantitative knowledge of the influence of the small airway disease on the functional changes in chronic obstructive pulmonary disease (COPD) patients has been severely limited.
Methods: This study presents an innovative patient-specific computational framework that integrates CT and OCT imaging data with multiscale computational fluid dynamics (CFD) analysis. A three-dimensional tracheobronchial tree is reconstructed from CT scans of a mild COPD patient, spanning from the central airway to the 4th generation bronchial bifurcations.